Eledon Pharmaceuticals Inc. (NASDAQ: ELDN)
$2.80
+0.1900 ( +7.28% ) 157.3K
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Market Data
Open
$2.80
Previous close
$2.61
Volume
157.3K
Market cap
$108.97M
Day range
$2.61 - $2.84
52 week range
$1.07 - $3.35
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Jul 12, 2024 |
8-k | 8K-related | 12 | Jul 10, 2024 |
8-k | 8K-related | 11 | Jul 10, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
ars | Annual reports | 1 | May 30, 2024 |
def | Proxies and info statements | 16 | May 30, 2024 |
10-q | Quarterly Reports | 63 | May 15, 2024 |